BioCentury | Apr 14, 2014
Product Development

Unlocking cancer data

...CRPC) (A) 526 Johnson & Johnson (NYSE:JNJ) Siltuximab (CNTO 328) Mitoxantrone Metastatic CRPC (A) 49 Novacea Inc....
...CRPC) (A) 526 Johnson & Johnson (NYSE:JNJ) Siltuximab (CNTO 328) Mitoxantrone Metastatic CRPC (A) 49 Novacea Inc....
BioCentury | Jun 1, 2009
Product Development

Hypoxic depth charge

...advanced hepatocellular carcinoma in combination with Nexavar sorafenib from Bayer AG and Onyx Pharmaceuticals Inc. Novacea Inc....
BioCentury | Mar 9, 2009
Company News

Spectrum Pharmaceuticals management update

...Pharmaceuticals Inc. ; and Amar Singh as chief commercial officer, previously chief commercial officer at Novacea Inc....
BioCentury | Feb 23, 2009
Company News

iZumi management update

...Gene/Cell therapy Hired: John Walker as CEO and a director, formerly chairman and CEO of Novacea Inc....
BioCentury | Feb 9, 2009
Company News

Novacea, Transcept deal

...The companies completed their previously announced reverse merger (see BioCentury, Sept. 8, 2008). Novacea Inc. (NASDAQ:NOVC), South...
BioCentury | Dec 22, 2008
Clinical News

Intermezzo zolpidem regulatory update

...a decision on the low-dose sublingual formulation of zolpidem in 4Q09. Transcept is reverse-merging with Novacea Inc....
BioCentury | Dec 22, 2008
Finance

Ebb & Flow

...Ipsen has European rights to the selective xanthine oxidase inhibitor from Teijin (see B11) . Novacea...
...NDA from Transcept for Intermezzo zolpidem to treat insomnia. Transcept, which is reverse merging into Novacea...
BioCentury | Dec 17, 2008
Company News

FDA accepts Intermezzo NDA

...of the Food, Drug and Cosmetic Act. Transcept is reverse-merging with Novacea (NASDAQ:NOVC). On Tuesday, Novacea...
BioCentury | Nov 17, 2008
Clinical News

Intermezzo regulatory update

...a middle of the night awakening is followed by difficulty returning to sleep. Transcept and Novacea Inc....
BioCentury | Sep 29, 2008
Analyst Picks & Changes

Analyst picks & changes

...pulmonary fibrosis (IPF). Shionogi has rights for fibrotic diseases in Japan, South Korea and Taiwan. Novacea...
Items per page:
1 - 10 of 128
BioCentury | Apr 14, 2014
Product Development

Unlocking cancer data

...CRPC) (A) 526 Johnson & Johnson (NYSE:JNJ) Siltuximab (CNTO 328) Mitoxantrone Metastatic CRPC (A) 49 Novacea Inc....
...CRPC) (A) 526 Johnson & Johnson (NYSE:JNJ) Siltuximab (CNTO 328) Mitoxantrone Metastatic CRPC (A) 49 Novacea Inc....
BioCentury | Jun 1, 2009
Product Development

Hypoxic depth charge

...advanced hepatocellular carcinoma in combination with Nexavar sorafenib from Bayer AG and Onyx Pharmaceuticals Inc. Novacea Inc....
BioCentury | Mar 9, 2009
Company News

Spectrum Pharmaceuticals management update

...Pharmaceuticals Inc. ; and Amar Singh as chief commercial officer, previously chief commercial officer at Novacea Inc....
BioCentury | Feb 23, 2009
Company News

iZumi management update

...Gene/Cell therapy Hired: John Walker as CEO and a director, formerly chairman and CEO of Novacea Inc....
BioCentury | Feb 9, 2009
Company News

Novacea, Transcept deal

...The companies completed their previously announced reverse merger (see BioCentury, Sept. 8, 2008). Novacea Inc. (NASDAQ:NOVC), South...
BioCentury | Dec 22, 2008
Clinical News

Intermezzo zolpidem regulatory update

...a decision on the low-dose sublingual formulation of zolpidem in 4Q09. Transcept is reverse-merging with Novacea Inc....
BioCentury | Dec 22, 2008
Finance

Ebb & Flow

...Ipsen has European rights to the selective xanthine oxidase inhibitor from Teijin (see B11) . Novacea...
...NDA from Transcept for Intermezzo zolpidem to treat insomnia. Transcept, which is reverse merging into Novacea...
BioCentury | Dec 17, 2008
Company News

FDA accepts Intermezzo NDA

...of the Food, Drug and Cosmetic Act. Transcept is reverse-merging with Novacea (NASDAQ:NOVC). On Tuesday, Novacea...
BioCentury | Nov 17, 2008
Clinical News

Intermezzo regulatory update

...a middle of the night awakening is followed by difficulty returning to sleep. Transcept and Novacea Inc....
BioCentury | Sep 29, 2008
Analyst Picks & Changes

Analyst picks & changes

...pulmonary fibrosis (IPF). Shionogi has rights for fibrotic diseases in Japan, South Korea and Taiwan. Novacea...
Items per page:
1 - 10 of 128